{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/headache-medication-overuse/","result":{"data":{"firstChapter":{"id":"40857afc-808e-588e-8df4-4d8b15ec657a","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 11660eb9-dc0d-4a32-b49e-f50a04145f29 --><h1>Headache - medication overuse: Summary</h1><!-- end field 11660eb9-dc0d-4a32-b49e-f50a04145f29 -->","htmlStringContent":"<!-- begin item efd6acca-271c-4013-b96c-4570b34e7991 --><!-- begin field dff70f59-1708-4050-996e-58b45514add4 --><ul><li>Medication overuse headache is a chronic headache which results from regular overuse of headache medication such as ergotamine, triptans, opioids, nonsteroidal anti-inflammatories (including aspirin), and paracetamol.<ul><li>The headache usually (but not always) resolves following cessation of the overused medication.</li></ul></li><li>The pathophysiology of medication overuse headache is not clear but may involve interaction between excessive use of a drug and individual susceptibility.</li><li>Medication overuse headache is estimated to occur in 1-2% of the general population worldwide and is more prevalent in women.</li><li>Diagnostic criteria for medication overuse headache include:<ul><li>Headache occurring on 15 or more days per month in a person with a pre-existing headache disorder <em>and</em></li><li>Regular overuse for more than 3 months of one or more drugs that can be taken for acute and/or symptomatic treatment of headache.<ul><li>For ergotamine, triptans, opioids and combination analgesics intake must be 10 days or more per month to be considered overuse.</li><li>For simple analgesics such as nonsteroidal anti-inflammatories (including aspirin) and paracetamol intake must be 15 days or more per month to be considered overuse.</li></ul></li><li>Headache must not be better accounted for by another headache diagnosis.</li></ul></li><li>Management of medication overuse headache involves:<ul><li>Explaining the diagnosis and the importance of withdrawal of overused medication.</li><li>Discussion with or referral to a specialist in neurology if overuse involves opioids or tranquillizers, significant comorbidities are present or previous repeated withdrawal attempts have been unsuccessful in primary care. Inpatient withdrawal may be required.</li><li>Advising the person to stop taking all overused headache medications for at least one month.</li><li>Warning the person that withdrawal may initially worsen symptoms and headache improvement may not occur for weeks after discontinuation.</li><li>Managing associated comorbidities such as anxiety and depression.</li><li>Providing close follow up and support to help prevent relapse.</li><li>Reviewing the person 4–8 weeks after withdrawal of the overused medication to review the diagnosis and assess the need for further management of an underlying primary headache disorder.</li></ul></li><li>Referral to (or discussion with) a neurologist or GP with a special interest in headache is indicated if uncertain about the diagnosis or management or first line measures in primary care fail.</li></ul><!-- end field dff70f59-1708-4050-996e-58b45514add4 --><!-- end item efd6acca-271c-4013-b96c-4570b34e7991 -->","topic":{"id":"c3e2af9a-7e39-5197-9eb3-1ed7a0e55408","topicId":"876b21f6-c785-4745-8233-2a56adca5e2f","topicName":"Headache - medication overuse","slug":"headache-medication-overuse","aliases":[],"chapters":[{"id":"40857afc-808e-588e-8df4-4d8b15ec657a","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"63871d8d-20ed-5111-b909-c671b7d8290d","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"9cae9867-86cc-59c4-b6bf-f373dcba4164","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"8249aff5-50e4-5d82-9408-80a413334b35","slug":"changes","fullItemName":"Changes"},{"id":"db547c32-5bee-554a-a0b2-dc3586cf0545","slug":"update","fullItemName":"Update"}]},{"id":"2abe896d-4027-5ea6-b53c-4126bd2728c4","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"38f0d3b1-709d-5342-b729-a1341e432308","slug":"goals","fullItemName":"Goals"},{"id":"a38c1ab1-09de-5ef7-baff-841d15605039","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"43907ef2-b709-5ebe-b83b-ab23bc9ed6ca","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"0feb34c0-feb0-5b65-a4c1-32baeee2a780","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"dd0c4d51-1d5a-5ed5-913d-c4891dbdcdad","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5b6a60a6-ec80-5422-af6f-b6397fc4eb49","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3cd81fd7-0d7a-552d-84fc-71226d45fd89","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"3d866153-0662-5ce8-b955-3970472be336","slug":"definition","fullItemName":"Definition"},{"id":"d33eb885-20a8-5803-a999-aceb7adffb72","slug":"causes","fullItemName":"Causes"},{"id":"f8475e5f-a2f9-5002-932a-d7ba4870aa9f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a1c40b6b-4520-56e8-b2fa-bb765751e34f","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"b50624f5-1fc7-5aae-8abf-9c5d20c25996","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"c264e53b-3cbc-5157-819e-b2829d10ddf3","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"7a8b4459-1ea1-567d-894f-eee914a8f3e0","slug":"assessment","fullItemName":"Assessment"},{"id":"0fffe194-2a62-5cc8-921c-70edbfaaee2f","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"24bded00-bd1c-5e35-8d9e-e9cbdb170491","slug":"management","fullItemName":"Management","subChapters":[{"id":"5aa2d427-7d2b-5110-b3c3-149b3c9ae20f","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"2d1b86f8-d377-5c3d-9334-138f4cdb5622","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"e8ea0b38-7c95-5427-8107-b6506325dd95","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"83630e7e-e220-5043-af84-8cf6a05f13d4","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"9d829e6b-790e-5c8c-b792-58adea1a2dd3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7de26ebd-eda1-5880-8547-e657d94fc6a0","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e74b3fd8-6eac-5d2e-886c-97583955d536","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3ce1ab25-89c2-5795-9e6a-493771574210","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"78c55256-334c-5f3e-8d0f-80013fc16bc9","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"c3e2af9a-7e39-5197-9eb3-1ed7a0e55408","topicId":"876b21f6-c785-4745-8233-2a56adca5e2f","topicName":"Headache - medication overuse","slug":"headache-medication-overuse","aliases":[],"topicSummary":"Medication overuse headache results from regular overuse of headache medication such as ergotamine, triptans, opioids, or other analgesics","lastRevised":"Last revised in November 2017","nextPlannedReviewBy":"2022-11-01T00:00:00+00:00","nextPlannedReviewByDateTime":"2022-11","nextPlannedReviewByDisplay":"November 2022","specialities":[{"id":"08590215-7450-5fd4-bb09-b98865ce23ee","name":"Neurological","slug":"neurological"}],"chapters":[{"id":"40857afc-808e-588e-8df4-4d8b15ec657a","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"63871d8d-20ed-5111-b909-c671b7d8290d","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"9cae9867-86cc-59c4-b6bf-f373dcba4164","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"8249aff5-50e4-5d82-9408-80a413334b35","slug":"changes","fullItemName":"Changes"},{"id":"db547c32-5bee-554a-a0b2-dc3586cf0545","slug":"update","fullItemName":"Update"}]},{"id":"2abe896d-4027-5ea6-b53c-4126bd2728c4","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"38f0d3b1-709d-5342-b729-a1341e432308","slug":"goals","fullItemName":"Goals"},{"id":"a38c1ab1-09de-5ef7-baff-841d15605039","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"43907ef2-b709-5ebe-b83b-ab23bc9ed6ca","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"0feb34c0-feb0-5b65-a4c1-32baeee2a780","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"dd0c4d51-1d5a-5ed5-913d-c4891dbdcdad","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5b6a60a6-ec80-5422-af6f-b6397fc4eb49","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3cd81fd7-0d7a-552d-84fc-71226d45fd89","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"3d866153-0662-5ce8-b955-3970472be336","slug":"definition","fullItemName":"Definition"},{"id":"d33eb885-20a8-5803-a999-aceb7adffb72","slug":"causes","fullItemName":"Causes"},{"id":"f8475e5f-a2f9-5002-932a-d7ba4870aa9f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a1c40b6b-4520-56e8-b2fa-bb765751e34f","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"b50624f5-1fc7-5aae-8abf-9c5d20c25996","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"c264e53b-3cbc-5157-819e-b2829d10ddf3","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"7a8b4459-1ea1-567d-894f-eee914a8f3e0","slug":"assessment","fullItemName":"Assessment"},{"id":"0fffe194-2a62-5cc8-921c-70edbfaaee2f","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"24bded00-bd1c-5e35-8d9e-e9cbdb170491","slug":"management","fullItemName":"Management","subChapters":[{"id":"5aa2d427-7d2b-5110-b3c3-149b3c9ae20f","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"2d1b86f8-d377-5c3d-9334-138f4cdb5622","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"e8ea0b38-7c95-5427-8107-b6506325dd95","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"83630e7e-e220-5043-af84-8cf6a05f13d4","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"9d829e6b-790e-5c8c-b792-58adea1a2dd3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7de26ebd-eda1-5880-8547-e657d94fc6a0","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e74b3fd8-6eac-5d2e-886c-97583955d536","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3ce1ab25-89c2-5795-9e6a-493771574210","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"78c55256-334c-5f3e-8d0f-80013fc16bc9","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"c3e2af9a-7e39-5197-9eb3-1ed7a0e55408"}},"staticQueryHashes":["3666801979"]}